Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Diabetes Care. 2014 Jun;37(6):1729-36. doi: 10.2337/dc13-2704. Epub 2014 Apr 2.
There is no information about the role of nonalcoholic fatty liver disease (NAFLD) in predicting the development of chronic kidney disease (CKD) in type 1 diabetes.
We studied 261 type 1 diabetic adults with preserved kidney function and with no macroalbuminuria at baseline, who were followed for a mean period of 5.2 years for the occurrence of incident CKD (defined as estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 and/or macroalbuminuria). NAFLD was diagnosed by ultrasonography.
At baseline, patients had a mean eGFR of 92 ± 23 mL/min/1.73 m2; 234 (89.7%) of them had normoalbuminuria and 27 (10.3%) microalbuminuria. NAFLD was present in 131 (50.2%) patients. During follow-up, 61 subjects developed incident CKD. NAFLD was associated with an increased risk of incident CKD (hazard ratio [HR] 2.85 [95% CI 1.59-5.10]; P < 0.001). Adjustments for age, sex, duration of diabetes, hypertension, A1C, and baseline eGFR did not appreciably attenuate this association (adjusted HR 2.03 [1.10-3.77], P < 0.01). Results remained unchanged after excluding those who had microalbuminuria at baseline (adjusted HR 1.85 [1.03-3.27]; P < 0.05). Addition of NAFLD to traditional risk factors for CKD significantly improved the discriminatory capability of the regression models for predicting CKD (e.g., with NAFLD c statistic 0.79 [95% CI 0.73-0.86] vs. 0.76 [0.71-0.84] without NAFLD, P = 0.002).
This is the first study to demonstrate that NAFLD is strongly associated with an increased incidence of CKD. Measurement of NAFLD improves risk prediction for CKD, independently of traditional cardio-renal risk factors, in patients with type 1 diabetes.
目前尚无关于非酒精性脂肪性肝病(NAFLD)在预测 1 型糖尿病患者慢性肾脏病(CKD)发展中的作用的信息。
我们研究了 261 例基线时肾功能正常且无大量白蛋白尿的 1 型糖尿病成年患者,这些患者平均随访 5.2 年,以观察是否发生 CKD 事件(定义为估算肾小球滤过率[eGFR]<60ml/min/1.73m2和/或出现大量白蛋白尿)。通过超声检查诊断 NAFLD。
基线时,患者的平均 eGFR 为 92±23ml/min/1.73m2;234 例(89.7%)患者为正常白蛋白尿,27 例(10.3%)为微量白蛋白尿。131 例(50.2%)患者存在 NAFLD。随访期间,有 61 例发生 CKD 事件。NAFLD 与 CKD 事件风险增加相关(风险比[HR]2.85[95%CI 1.59-5.10];P<0.001)。调整年龄、性别、糖尿病病程、高血压、A1C 和基线 eGFR 后,这种相关性并未明显减弱(调整 HR 2.03[1.10-3.77],P<0.01)。在排除基线时有微量白蛋白尿的患者后,结果仍然不变(调整 HR 1.85[1.03-3.27];P<0.05)。将 NAFLD 加入到 CKD 的传统危险因素中,显著提高了预测 CKD 的回归模型的判别能力(例如,有 NAFLD 时的 c 统计量为 0.79[95%CI 0.73-0.86],而无 NAFLD 时为 0.76[0.71-0.84],P=0.002)。
这是第一项表明 NAFLD 与 CKD 发生率增加密切相关的研究。在 1 型糖尿病患者中,NAFLD 的测量可改善 CKD 的风险预测,独立于传统的心肾危险因素。